Patients as Research Drivers
For many rare diseases, patient advocacy organizations founded by affected families have become powerful and often underappreciated drivers of research progress, filling gaps left by limited pharmaceutical industry investment and modest government research funding for individually rare conditions, and in some cases directly funding and accelerating research that led to approved treatments that might otherwise never have been developed.
How Advocacy Groups Accelerate Progress
These organizations often fund research grants directly, sometimes providing crucial early-stage funding that helps researchers generate preliminary data needed to attract larger institutional funding. They establish patient registries that provide invaluable natural history data about disease progression, essential for designing clinical trials, and they connect researchers with patient populations that would otherwise be extremely difficult to identify and recruit given how rare and geographically dispersed patients with any single rare disease typically are.
A Model of Patient-Driven Progress
Beyond direct research funding, rare disease advocacy groups provide crucial peer support and information for newly diagnosed families, advocate for policy changes supporting rare disease research and access, and in some notable cases have directly partnered with researchers and companies to accelerate specific treatment development. This patient-driven model of medical progress, born of necessity given how rare disease research is chronically underfunded, offers lessons for advancing other under-resourced areas of medicine. Facilities can source lab supplies and patient care supplies from our catalog.
